全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

青岛大学附属医院COVID-19患者临床特点及治疗分析
Clinical Characteristics and Treatment of COVID-19 Patients in the Affiliated Hospital of Qingdao University

DOI: 10.12677/ACM.2020.107190, PP. 1246-1251

Keywords: COVID-19，临床特点，治疗
COVID-19, Clinical Characteristics, Treatment

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的：2019年12月，新型冠状病毒肺炎疫情(Coronavirus Disease 2019)在中国爆发。本研究的目的是让临床医生更深入地了解这种新的传染病。方法：收集青岛大学附属医院收治的23例COVID-19患者的流行病学、临床特征、实验室检查、影像学特征、治疗及临床转归等资料进行分析。结果：共纳入23例COVID-19住院患者，中位年龄为43.0岁(IQR 31-57)，没有显著的性别差异(56.5%的女性)，大多数患者有武汉旅居史，大多数患者的胸部CT显示双侧斑片状影或磨玻璃样影。所有患者均接受了抗病毒治疗和糖皮质激素(8例[40%])。除1例死亡病例，1例患者还在住院外，21例患者均已出院，平均住院日为14.52天。结论：本文对23例COVID-19患者的临床特点及治疗方法进行了研究，目前尚无治疗COVID-19的有效抗病毒药物，应避免盲目或不恰当使用抗菌药物，仍需要进一步的临床试验来证实激素的临床益处。
Objective: In December 2019, COVID-19 broke out in China. The purpose of this study is to provide clinicians with a better understanding of this new infectious disease. Methods: The data of epidemiology, clinical features, laboratory examination, imaging features, treatment and clinical outcomes of 23 patients admitted to the affiliated hospital of Qingdao university were collected and analyzed. Results: A total of 23 COVID-19 in patients were enrolled. The median age was 43.0 years (IQR 31-57), with no significant gender difference (56.5% of women). Most of the patients had a history of sojourn in Wuhan. Most patients have bilateral patchy or ground-glass images on chest CT. All patients received antiviral therapy and glucocorticoids (8 cases [40%]). In addition to one death and one patient in hospital, all 21 patients were discharged with an average length of stay of 14.52 days. Conclusion: In this study, the clinical characteristics and treatment of 23 COVID-19 patients were studied. Currently, there are no effective antiviral drugs for COVID-19. Blind or inappropriate use of antimicrobial drugs should be avoided.

References

[1]  Phelan, A.L., Katz, R. and Gostin, L.O. (2020) The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA, 323, 709-710.
https://doi.org/10.1001/jama.2020.1097
[2]  Gorbalenya, A.E., Baker, S.C., Baric, R.S., et al. (2020) Severe Acute Respiratory Syndrome-Related Coronavirus: The Species and Its Viruses—A Statement of the Coronavirus Study Group. bioRxiv.
https://doi.org/10.1101/2020.02.07.937862
[3]  Chan, J.W.M., Ng, C.K., Chan, Y.H., et al. (2003) Short Term Outcome and Risk Factors for Adverse Clinical Outcomes in Adults with Severe Acute Respiratory Syndrome (SARS). Thorax, 58, 686-689.
https://doi.org/10.1136/thorax.58.8.686
[4]  World Health Organization (2020) Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection Is Suspected: Interim Guidance, 28 January 2020. World Health Organization, Geneva.
[5]  Diagnosis and Treatment of Novel Coronavirus Pneumonia (Trial Version Fifth). Chinese Journal of Integrated Traditional and Western Medicine, 1-3. http://kns.cnki.net/kcms/detail/11.2787.R.20200208.1034.002.html
[6]  Phan, L.T., Nguyen, T.V., Luong, Q.C., Nguyen, T.V., Nguyen, H.T., Le, H.Q., et al. (2020) Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. New England Journal of Medicine, 382, 872-874.
https://doi.org/10.1056/NEJMc2001272
[7]  Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA, 323, 1061-1069.
https://doi.org/10.1001/jama.2020.1585
[8]  Yu, P., Zhu, J., Zhang, Z., Han, Y. and Huang, L. (2020) A Familial Cluster of Infection Associated with the 2019 Novel Coronavirus Indicating Potential Person-to-Person Transmission during the Incubation Period. The Journal of Infectious Diseases, 221, 1757-1761.
https://doi.org/10.1093/infdis/jiaa077
[9]  余进, 刘伟, 陈伟, 等. 关于重症新型冠状病毒肺炎继发侵袭性真菌感染实验室诊治建议[J]. 中国真菌学杂志, 2020, 15(1): 1-5.
[10]  Shang, L., Zhao, J., Hu, Y., Du, R. and Cao, B. (2020) On the USE of corticosteroids for 2019-nCoV Pneumonia. The Lancet, 395, 683-684.
https://doi.org/10.1016/S0140-6736(20)30361-5
[11]  Stockman, L.J., Bellamy, R. and Garner, P. (2006) SARS: Systematic Review of Treatment Effects. PLoS Medicine, 3, e343.
https://doi.org/10.1371/journal.pmed.0030343
[12]  Chen, R.-C., Tang, X.-P., Tan, S.-Y., Liang, B.-L., Wan, Z.-Y., Fang, J.-Q., et al. (2006) Treatment of Severe Acute Respiratory Syndrome with Glucosteroids: The Guangzhou Experience. Chest, 129, 1441-1452.
https://doi.org/10.1378/chest.129.6.1441
[13]  Zhao, J., Hu, Y., Du, R., Chen, Z., Jin, Y., Zhou, M., et al. (2020) Expert Consensus on the Use of Corticosteroid in Patients with 2019-nCoV Pneumonia. Chinese Journal of Tuberculosis and Respiratory Diseases, 43, E007.
[14]  Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H.R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R.A.., et al. (2003) Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. The New England Journal of Medicine, 348, 1967-1976.
https://doi.org/10.1056/NEJMoa030747
[15]  Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J.A., Lim, W., et al. (2003) A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. The New England Journal of Medicine, 348, 1953-1966.
https://doi.org/10.1056/NEJMoa030781
[16]  Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D. and Fouchier, R.A. (2012) Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. The New England Journal of Medicine, 367, 1814-1820.
https://doi.org/10.1056/NEJMoa1211721
[17]  Zhong, N.S., Zheng, B.J., Li, Y.M., Poon, L.L.M., Xie, Z.H., Chan, K.H., Li, P.H., Tan, S.Y., Chang, Q., Xie, J.P., et al. (2003) Epidemiology and Cause of Severe Acute Respiratory Syndrome (Sars) in Guangdong, People’s Republic of China, in February, 2003. Lancet (Lond. Engl.), 362, 1353-1358.
https://doi.org/10.1016/S0140-6736(03)14630-2
[18]  Kui, L., Fang, Y.Y., Deng, Y., Liu, W., Wang, M.F., Ma, J.P., et al. (2020) Clinical Characteristics of Novel Coronavirus Cases in Tertiary Hospitals in Hubei Province. Chinese Medical Journal.
[19]  Jiang, X., Rayner, S. and Luo, M.-H. (2020) Does SARS-CoV-2 Have a Longer Incubation Period than SARS and MERS? Journal of Medical Virology, 92, 476-478.
https://doi.org/10.1002/jmv.25708
[20]  Lu, H., Stratton, C.W. and Tang, Y.W. (2020) Outbreak of Pneumonia of Unknown Etiology in Wuhan China: The Mystery and the Miracle. Journal of Medical Virology, 92, 401-402.
https://doi.org/10.1002/jmv.25678
[21]  Hui, D.S., Azhar, E.I., Madani, T.A., et al. (2020) The Continuing COVID-19 Epidemic Threat of Novel Coronaviruses to Global Health—The Latest 2019 Novel Coronavirus Outbreak in Wuhan, China. International Journal of Infectious Diseases, 91, 264-266.
https://doi.org/10.1016/j.ijid.2020.01.009
[22]  Huang, C., Wang, Y., Li, X., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet, 395, 497-506.
https://doi.org/10.1016/S0140-6736(20)30183-5
[23]  Yang, Y.S., Peng, F.J., Wang, R.S., Guan, K., Jiang, T.J., Xu, G.G., Sun, J. and Chang, C. (2020) The Deadly Coronaviruses: The 2003 SARS Pandemic and the 2020 Novel Coronavirus Epidemic in China. Journal of Autoimmunity, 109, 102434.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133